Praxis Precision Medicines Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
PRAX$332.97+19.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $81,300 | $61,615 |
| Marketable securities | — | 38,874 |
| Prepaid expenses and other current assets | 3,580 | 10,351 |
| Total current assets | 84,880 | 110,840 |
| Property and equipment, net | 588 | 971 |
| Operating lease right-of-use assets | 2,064 | 2,901 |
| Other non-current assets | 416 | 416 |
| Total assets | $87,948 | $115,128 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,815 | $14,672 |
| Accrued expenses | 7,416 | 15,850 |
| Operating lease liabilities | 1,126 | 1,005 |
| Current portion of deferred revenue | 1,392 | 2,818 |
| Total current liabilities | 15,749 | 34,345 |
| Long-term liabilities: | ||
| Non-current portion of operating lease liabilities | 1,369 | 2,495 |
| Non-current portion of deferred revenue | 1,161 | 2,182 |
| Total liabilities | 18,279 | 39,022 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and December 31, 20221 | — | — |
| Common stock, 0.0001 par value; 150,000,000.00 shares authorized; 8,791,877 shares issued and outstanding as of December 31, 2023, and 3,292,163 shares issued and outstanding as of December 31, 20221 | 13 | 5 |
| Additional paid-in capital | 723,577 | 606,918 |
| Accumulated other comprehensive loss | — | (173) |
| Accumulated deficit | (653,921) | (530,644) |
| Total stockholders’ equity | 69,669 | 76,106 |
| Total liabilities and stockholders’ equity | $87,948 | $115,128 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.